INCLUSION FOR CURRENT ENROLLING TRIALS

DIABETIC RETINOPATHY

The Photon Study-
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease. Comparing Aflibercept versus High-dose Aflibercept.

Study is for two years with monthly appointments.
- Be aged 18 years or over.
- Have a confirmed diagnosis of Diabetes

The New Day Study-
A Study of Intraviteral ILUVIEN Implant as Baseline Therapy in Patients With Diabetic Macular Edema. Comparing Aflibercept to Iluvien 0.19 MG Drug Implant.

Study is for 18 months with monthly visits.
- Male or females patient ≥18 years of age at the time of consent.
- Diagnosis of Type 1 or Type 2 Diabetes
- Must have CI-DME confirmed by Spectral Domain OCT
- Treatment Naive

The Glim/Glimmer Study-
A Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME. Comparing Aflibercept to KSI-301 to Sham Procedure.

Study is for 2 years with monthly visits.
- A1C ≤12 %
- Diagnosis of Type 1 or Type 2 Diabetes Mellitus
- Treatment Naive

The Glow Study-
A Phase 3, Prospective, Randomized, Double-masked, Sham Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Participants with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR). Comparing Aflibercept to KSI-301 to Sham Procedure.

Study is for 2 years with monthly treatments
- Nonproliferative Diabetic Retinopathy with no DME
- DRSS Levels 47 or 53
- Treatment Naïve

MACULAR DEGENERATION

SCD411 Study-
A Study to Comparing SCD411 and Eylea in Subjects With Age-Related Macular Degeneration (AMD). Comparing Aflibercept versus SCD411 Drug.

Study is for 1 year with monthly appointments.
- Age ≥50 years.
- New diagnosis of AMD in either eye
- Treatment Naïve

The Golden Study-
Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geography Atrophy (GA) Secondary to Age-Related Macular Degeneration. Comparing IONIS-FB-Lrx versus Placebo (sterline saline .09%) subcutaneous treatment.

Study is for one year with monthly visits.
- Be at least 50 years of age
- Have a medical diagnosis of AMD in at least one eye



PROLIFERATIVE VITREORETINOPATHY

The Guard Study-
Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy Comparing Standard Surgical Care to Intravitreal Methotrexate 0.8%.

Study is 16 weeks. Patients can be seen weekly or monthly depending on which arm they randomize in.
- Diagnosis of Retinal Detachment with PVR in either eye
- Subject is 18 years or older of any gender or race

BLUE OCEAN CLINICAL RESEARCH

The Macula Center

For More information on these clinical trials please visit: www.clinicaltrials.gov

Call us:
727-789-8770
MaculaCenter.com/studies

SCAN ME